Table 1A.
Summary of Patient Characteristics
| Overall (N = 911) | Non-recurrent NMIBC (N = 306) | Recurrent NMIBC (N = 272) | MIBC (N = 270) | Metastatic bladder cancer (n = 63) | p-value | |
| Age | 67.6 (8.7) [68] | 68.3 (9.0) [69] | 66.7 (8.4) [68] | 67.4 (8.8) [67] | 68.5 (7.9) [68.5] | 0.09 |
| Gender, N (%) | ||||||
| Male | 468 (51%) | 166 (54%) | 127 (47%) | 146 (54%) | 29 (46%) | 0.16 |
| Female | 320 (35%) | 93 (30%) | 112 (41%) | 91 (34%) | 24 (38%) | 0.06 |
| Missing | 123 (14%) | 47 (15%) | 33 (12%) | 33 (12%) | 10 (16%) | |
| Race, N (%) | 0.8 | |||||
| White/Caucasian | 772 (79%) | 244 (80%) | 229 (84%) | 226 (84%) | 53 (84%) | |
| Black or African American | 12 (1%) | 6 (2%) | 2 (0.7%) | 3 (1%) | 0 | |
| American Indian or Alaska Native | 3 (0.3%) | 2 (0.6%) | 1 (0.4%) | 0 | 0 | |
| Asian | 9 (0.9%) | 2 (0.6%) | 2 (0.7%) | 4 (1.5%) | 0 | |
| Native Hawaiian or Pacific Islander | 0 (0%) | 1 (0.3%) | 0 | 0 | 0 | |
| Missing | 175 (18%) | 51 (17%) | 38 (14%) | 37 (14%) | 10 (16%) | |
| Ethnicity, N (%) | ||||||
| Hispanic | 16 (2%) | 5 (1.6%) | 5 (2%) | 6 (2%) | 0 | 0.57 |
| Non-Hispanic | 748 (82%) | 247 (81%) | 225 (83%) | 227 (84%) | 49 (78%) | |
| Missing | 147 (16%) | 54 (18%) | 42 (15%) | 37 (14%) | 14 (22%) | |
| Region of current residence, N (%) | 0.21 | |||||
| Northeast | 159 (17%) | 44 (14%) | 59 (22%) | 47 (17%) | 9 (14%) | |
| Midwest | 160 (18%) | 52 (17%) | 42 (15%) | 56 (21%) | 10 (16%) | |
| South | 233 (26%) | 86 (28%) | 76 (28%) | 58 (21%) | 13 (21%) | |
| West | 173 (19%) | 60 (20%) | 43 (16%) | 57 (21%) | 13 (21%) | |
| Missing | 186 (20%) | 64 (21%) | 52 (19%) | 52 (19%) | 18 (29%) | |
| Highest level of formal education, N (%) | ||||||
| 8th grade or less | 1 (0%) | 0 | 0 | 0 | 1 (2%) | 0.03 |
| Some high school | 2 (0%) | 1 (0.3%) | 0 | 0 | 1 (2%) | |
| High school graduate | 55 (6%) | 16 (5%) | 16 (6%) | 17 (6%) | 6 (9%) | |
| Some college (did not complete) | 199 (22%) | 61 (20%) | 63 (23%) | 62 (23%) | 13 (21%) | |
| College graduate | 253 (28%) | 86 (28%) | 67 (25%) | 87 (32%) | 13 (21%) | |
| Post-college degree | 277 (30%) | 95 (31%) | 92 (34%) | 72 (27%) | 18 (29%) | |
| Missing | 124 (14%) | 47 (15%) | 34 (12%) | 32 (12%) | 11 (17%) | |
| Annual household income, N (%) | ||||||
| Less than $20,000 | 29 (3%) | 12 (4%) | 3 (1%) | 12 (4%) | 2 (3%) | 0.33 |
| Between $20,001 and $40,000 | 82 (9%) | 29 (9%) | 26 (10%) | 22 (8%) | 5 (8%) | |
| Between $40,001 and $60,000 | 106 (12%) | 29 (9%) | 35 (13% | 37 (14%) | 6 (9%) | |
| Between $60,001 and $80,000 | 120 (13%) | 40 (13%) | 34 (12%) | 36 (13%) | 10 (16%) | |
| Between $80,001 and $100,000 | 106 (12%) | 34 (11%) | 24 (9%) | 38 (14%) | 10 (16%) | |
| More than $100,001 | 281 (31%) | 101 (33%) | 95 (35%) | 71 (26%) | 14 (22%) | |
| Missing | 187 (21%) | 62 (20%) | 55 (20%) | 54 (20%) | 16 (25%) | |
| Marital status, N (%) | ||||||
| Married | 594 (65%) | 188 (61%) | 185 (68%) | 186 (69%) | 35 (56%) | 0.2 |
| Unmarried, living with partner | 17 (2%) | 7 (2%) | 6 (2%) | 4 (1%) | 0 | |
| Divorced | 76 (8%) | 26 (8%) | 23 (8%) | 21 (8%) | 6 (10%) | |
| Widowed | 52 (6%) | 17 (6%) | 15 (6%) | 15 (6%) | 5 (8%) | |
| Separated | 6 (1%) | 3 (1%) | 0 | 3 (1%) | 0 | |
| Single, never married | 38 (4%) | 16 (5%) | 5 (2%) | 10 (4%) | 7 (11%) | |
| Missing | 128 (14%) | 49 (16%) | 38 (14%) | 31 (11%) | 10 (16%) | |
| Insurance coverage, N (%) | ||||||
| Commercial insurance | 424 (47%) | 140 (46%) | 130 (48%) | 127 (47%) | 27 (43%) | 0.29 |
| Medicare | 170 (19%) | 69 (22%) | 45 (17%) | 46 (17%) | 10 (16%) | |
| Government | 48 (5%) | 12 (4%) | 12 (4%) | 18 (7%) | 6 (10%) | |
| No insurance | 15 (2%) | 2 (1%) | 4 (1%) | 8 (3%) | 1 (2%) | |
| I don’t know/missing | 254 (28%) | 83 (27%) | 81 (30%) | 71 (26%) | 19 (30%) | |
| Physician specialty, N (%) | ||||||
| General urologist | 316 (35%) | 152 (50%) | 121 (44%) | 39 (14%) | 4 (6%) | < 0.0001 |
| Urologic oncologist | 278 (31%) | 99 (32%) | 94 (35%) | 73 (27%) | 12 (19%) | |
| Multidisciplinary | 165 (18%) | 11 (4%) | 13 (5%) | 111 (41%) | 30 (48%) | |
| Missing | 152 (17%) | 44 (14%) | 44 (16%) | 47 (17%) | 17 (27%) | |
| Number of comorbidities, N (%) | ||||||
| None | 282 (31%) | 85 (28%) | 88 (32%) | 90 (33%) | 19 (30%) | 0.01 |
| 1 | 223 (24%) | 85 (28%) | 54 (20%) | 68 (25%) | 16 (25%) | |
| 2 | 192 (21%) | 54 (20%) | 14 (22%) | |||
| 3 or more | 196 (22%) | 63 (21%) | 65 (24%) | 55 (20%) | 13 (21%) | |
| Missing | 18 (2%) | 14 (5%) | 0 | 3 (1%) | 1 (2%) | |
| First stage of bladder cancer diagnosed, N (%) | ||||||
| Non-invasive cancer | 643 (71%) | 304 (99%) | 270 (99%) | 52 (19%) | 17 (27%) | < 0.0001 |
| Invasive cancer | 234 (26%) | 1 (0.3%) | 2 (0.7%) | 213 (79%) | 18 (29%) | |
| Metastatic cancer | 31 (3%) | 0 | 0 | 3 (1%) | 28 (44%) | |
| I don’t know/missing | 3 (0%) | 1 (0.3%) | 0 | 2 (0.7%) | 0 | |
| Highest stage of bladder cancer diagnosed, N (%) | ||||||
| Non-invasive cancer | 578 (63%) | 306 (100%) | 272 (100%) | 0 | 0 | n/a |
| Invasive cancer | 270 (28%) | 0 | 0 | 270 (100%) | 0 | |
| Metastatic cancer | 63 (7%) | 0 | 0 | 0 | 63 (100%) | |
| I don’t know/missing | 0 | 0 | 0 | 0 | 0 | |
| Kinds of treatments received for bladder, N (%) | ||||||
| TURBT | 710 (78%) | 254 (83%) | 252 (93%) | 162 (60%) | 42 (67%) | n/a |
| Radical cystectomy | 394 (43%) | 36 (12%) | 87 (32%) | 220 (81%) | 51 (81%) | |
| Partial cystectomy | 15 (2%) | 4 (1%) | 2 (0.7%) | 6 (2%) | 3 (5%) | |
| Chemotherapy IV | 227 (25%) | 11 (4%) | 13 (5%) | 156 (58%) | 47 (75%) | |
| Immunotherapy IV | 55 (6%) | 6 (2%) | 10 (4%) | 13 (5%) | 26 (41%) | |
| Radiation therapy | 36 (4%) | 1 (0.3%) | 2 (0.7%) | 24 (9%) | 9 (14%) | |
| Intravesical therapy | 544 (60%) | 224 (73%) | 229 (84%) | 71 (26%) | 20 (32%) | |
| Ureteroscopy w/ biopsy or fulguration | 46 (5%) | 16 (5%) | 20 (7%) | 7 (3%) | 3 (5%) | |
| Nephroureterectomy | 42 (5%) | 8 (3%) | 13 (5%) | 9 (3%) | 12 (19%) | |
| Other | 64 (7%) | 17 (6%) | 12 (19%) |